– USA, CA – Sagimet Biosciences, a clinical-stage biotechnology company, today announced the receipt of a crossover financing totaling $80 million, led by a public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise Associates, and Rock Springs Capital) along with new investors (Altium Capital, HM Capital, Invus and PFM Health Sciences).
Sagimet also informed about the appointment of Dr. Beth Seidenberg, MD, general partner at Kleiner Perkins and founding managing director at Westlake Village Biopartners, as board chair, while Matt McAviney, principal at NEA, also joined the board as a director in January 2021.
“I am pleased to welcome leading public equity healthcare investors into the Sagimet investor syndicate. Their participation in this round of financing is a validation of Sagimet’s promising mechanism to combat NASH and the potential value established by the safety and efficacy profile of TVB-2640 as demonstrated to date,” said Dr. Seidenberg. “On behalf of the board, I look forward to supporting the company’s important work for the potential benefit of patients.”
Funds raised will support the advancement of TVB-2640, an oral, first-in-class fatty acid synthase inhibitor, including a planned Phase 2b trial evaluating the impact on histological endpoints. In Sagimet’s recent Phase 2 randomized placebo-controlled trial (FASCINATE-1), TVB-2640 significantly decreased liver fat and improved serum biomarkers of liver injury, fibrosis, and inflammation in patients with nonalcoholic steatohepatitis.
“We are extremely fortunate to have formed an investment syndicate of this caliber enabling us to advance our lead program, TVB-2640 for NASH, and to explore additional indications. We also plan to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021 that, together with TVB-2640, brings us another step closer to helping patients.” said CEO, Dr. George Kemble.
About Sagimet
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.
For more information: https://www.sagimet.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.